Feng-Lei Sun
Overview
Explore the profile of Feng-Lei Sun including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
68
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Han L, Zhang X, Zhang H, Li T, Zhao Y, Tian M, et al.
J Integr Med
. 2024 Feb;
22(1):83-92.
PMID: 38311542
Objective: Obesity is a global health concern with management strategies encompassing bariatric surgery and anti-obesity drugs; however, concerns regarding complexities and side effects persist, driving research for more effective, low-risk...
2.
Song Z, Liu Z, Sun J, Sun F, Li C, Sun J, et al.
Oncol Rep
. 2015 Oct;
35(1):127-38.
PMID: 26498848
Despite evidence that MRTF-A/B, co-activators of serum response factor (SRF), promotes tumor cell invasion and metastasis in cancer, there are no studies describing MRTF-A/B in pancreatic cancer. To clarify involvement...
3.
Sun X, Sun F, Du J, Pan Q, Zhang Y, Xu Y, et al.
Guang Pu Xue Yu Guang Pu Fen Xi
. 2009 Oct;
29(7):1750-3.
PMID: 19798932
The aim of the present research is to establish the cell basis for the carcinoma tissue diagnosis by exploring a method to obtain the FTIR (Fourier transform infrared spectra) of...
4.
Wang J, Rajput A, Kan J, Rose R, Liu X, Kuropatwinski K, et al.
J Biol Chem
. 2009 Feb;
284(16):10912-22.
PMID: 19224914
Abnormal accumulation and activation of receptor tyrosine kinase Ron (recepteur d'origine nantais) has been demonstrated in a variety of primary human cancers. We show that RNA interference-mediated knockdown of Ron...
5.
Mulvihill M, Kan J, Cooke A, Bhagwat S, Beck P, Bittner M, et al.
Bioorg Med Chem Lett
. 2006 Mar;
16(10):2729-33.
PMID: 16504501
3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid and analogs were designed and synthesized as highly potent and selective CYP26 inhibitors, serving as retinoic acid metabolic blocking agents (RAMBAs), with demonstrated in vivo efficacy to increase...
6.
Mulvihill M, Kan J, Beck P, Bittner M, Cesario C, Cooke A, et al.
Bioorg Med Chem Lett
. 2005 Mar;
15(6):1669-73.
PMID: 15745819
A series of [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines were designed and synthesized as CYP26 inhibitors, serving as retinoic acid metabolic blocking agents (RAMBA's).